GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirum Pharmaceuticals Inc (FRA:08D) » Definitions » Additional Paid-In Capital

Mirum Pharmaceuticals (FRA:08D) Additional Paid-In Capital : €750.8 Mil(As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Mirum Pharmaceuticals Additional Paid-In Capital?


Mirum Pharmaceuticals's quarterly additional paid-in capital declined from Sep. 2023 (€741.3 Mil) to Dec. 2023 (€736.6 Mil) but then increased from Dec. 2023 (€736.6 Mil) to Mar. 2024 (€750.8 Mil).

Mirum Pharmaceuticals's annual additional paid-in capital increased from Dec. 2021 (€334.0 Mil) to Dec. 2022 (€505.1 Mil) and increased from Dec. 2022 (€505.1 Mil) to Dec. 2023 (€736.6 Mil).

Mirum Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Mirum Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirum Pharmaceuticals Additional Paid-In Capital Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 180.11 283.74 334.00 505.11 736.59

Mirum Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 526.74 531.21 741.27 736.59 750.84

Mirum Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Mirum Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Mirum Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Mirum Pharmaceuticals (FRA:08D) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirum Pharmaceuticals Inc (FRA:08D) » Definitions » Additional Paid-In Capital
Comparable Companies
XNCR BCRX DAWN IRON AUPH AMLX CLDX VIR GERN SLRN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
MIRM:USA MIRM:Mexico
Address
950 Tower Lane, Suite 1050, Foster City, CA, USA, 94404
Website
https://www.mirumpharma.com
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Mirum Pharmaceuticals (FRA:08D) Headlines

No Headlines